Balón liberador de sirolimus en el tratamiento del síndrome coronario agudo y crónico: el estudio PEACE, un subanálisis del registro EASTBOURNE

IF 5.9 2区医学 Q2 Medicine

Revista espanola de cardiologia Pub Date : 2024-07-01 DOI:10.1016/j.recesp.2023.11.013

Alessandra Laricchia , Irene Bossi , Roberto A. Latini , Chuey Y. Lee , Ignacio S. Pérez , Fabrizio Tomai , Amin A. Nuruddin , Dario Buccheri , Giuseppe Seresini , Raymundo Ocaranza , Gunasekaran Sengottvelu , Nicola Pesenti , Antonio Mangieri , Bernardo Cortese , en representación de los investigadores del estudio EASTBOURNE

{"title":"Balón liberador de sirolimus en el tratamiento del síndrome coronario agudo y crónico: el estudio PEACE, un subanálisis del registro EASTBOURNE","authors":"Alessandra Laricchia , Irene Bossi , Roberto A. Latini , Chuey Y. Lee , Ignacio S. Pérez , Fabrizio Tomai , Amin A. Nuruddin , Dario Buccheri , Giuseppe Seresini , Raymundo Ocaranza , Gunasekaran Sengottvelu , Nicola Pesenti , Antonio Mangieri , Bernardo Cortese , en representación de los investigadores del estudio EASTBOURNE","doi":"10.1016/j.recesp.2023.11.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><p>The PEACE study (Performance of a sirolimus-eluting balloon strategy in acute and chronic coronary syndromes) investigated for the first time whether a sirolimus-coated balloon (SCB) (Magic Touch, Concept Medical, India) is associated with different outcomes depending on whether it is used in acute coronary syndromes (ACS) or chronic coronary syndromes (CCS).</p></div><div><h3>Methods</h3><p>This was a post-hoc analysis from the all-comers EASTBOURNE Registry (<span>NCT03085823</span><svg><path></path></svg>). Out of 2083 patients enrolled, an SCB was used to treat 968 (46.5%) ACS and 1115 (53.5%) CCS patients. The primary endpoint was target lesion revascularization at 12 months, while secondary endpoints were angiographic success and major adverse cardiovascular events.</p></div><div><h3>Results</h3><p>Baseline demographics, mean reference vessel diameter and mean lesion length were comparable between ACS and CCS. Predilatation was more commonly performed in ACS (<em>P</em>  =.820) with limited bailout stenting. Similarly, at 12 months the cumulative incidence of target lesion revascularization (ACS 6.6% vs CCS 5.2%, <em>P</em>  =.009). In-stent restenosis showed a higher proportion of target lesion revascularization and major adverse cardiovascular events than de novo lesions, independently of the type of presentation at the index procedure.</p></div><div><h3>Conclusions</h3><p>This SCB shows good performance in terms of acute and 1-year outcomes independently of the clinical presentation.</p></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"77 7","pages":"Pages 527-536"},"PeriodicalIF":5.9000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de cardiologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0300893223005213","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and objectives

The PEACE study (Performance of a sirolimus-eluting balloon strategy in acute and chronic coronary syndromes) investigated for the first time whether a sirolimus-coated balloon (SCB) (Magic Touch, Concept Medical, India) is associated with different outcomes depending on whether it is used in acute coronary syndromes (ACS) or chronic coronary syndromes (CCS).

Methods

This was a post-hoc analysis from the all-comers EASTBOURNE Registry (NCT03085823). Out of 2083 patients enrolled, an SCB was used to treat 968 (46.5%) ACS and 1115 (53.5%) CCS patients. The primary endpoint was target lesion revascularization at 12 months, while secondary endpoints were angiographic success and major adverse cardiovascular events.

Results

Baseline demographics, mean reference vessel diameter and mean lesion length were comparable between ACS and CCS. Predilatation was more commonly performed in ACS (P = .007). SCB was inflated at a standard pressure in both groups with a slight trend toward longer inflation time in ACS. Angiographic success was high in both groups (ACS 97.4% vs CCS 97.7%, P = .820) with limited bailout stenting. Similarly, at 12 months the cumulative incidence of target lesion revascularization (ACS 6.6% vs CCS 5.2%, P = .258) was comparable between ACS and CCS. Conversely, a higher rate of major adverse cardiovascular events in acute presenters was mainly driven by myocardial infarction recurrencies (ACS 10.4% vs CCS 8.3%, P = .009). In-stent restenosis showed a higher proportion of target lesion revascularization and major adverse cardiovascular events than de novo lesions, independently of the type of presentation at the index procedure.

Conclusions

This SCB shows good performance in terms of acute and 1-year outcomes independently of the clinical presentation.

查看原文本刊更多论文

治疗急慢性冠状动脉综合征的西罗莫司涂层球囊：EASTBOURNE 研究的子分析

简介和目的 PEACE 研究（西罗莫司洗脱球囊在急性和慢性冠状动脉综合征中的应用）首次调查了西罗莫司涂层球囊（SCB）（Magic Touch，印度 Concept Medical 公司）在急性冠状动脉综合征（ACS）和慢性冠状动脉综合征（CCS）中的应用是否会导致不同的结果。方法这是对所有患者的 EASTBOURNE 登记（NCT03085823）进行的一项事后分析。在入组的2083名患者中，968名（46.5%）ACS患者和1115名（53.5%）CCS患者接受了SCB治疗。结果 ACS和CCS的基线人口统计学、平均参考血管直径和平均病变长度相当。ACS 患者更常进行扩张术（P = .007）。两组患者均以标准压力对 SCB 进行充气，但 ACS 患者的充气时间略有延长。两组的血管造影成功率都很高（ACS 97.4% vs CCS 97.7%，P = .820），保送支架的成功率有限。同样，在 12 个月时，ACS 和 CCS 的靶病变血运重建累积发生率相当（ACS 6.6% vs CCS 5.2%，P = .258）。相反，急性期患者的主要不良心血管事件发生率更高，主要原因是心肌梗死复发（ACS 10.4% vs CCS 8.3%，P = .009）。支架内再狭窄的靶病变血运重建比例和主要不良心血管事件发生率均高于新生病变，与指数手术时的表现类型无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista espanola de cardiologia 医学-心血管系统

CiteScore

4.20

自引率

13.60%

发文量

257

审稿时长

28 days

期刊介绍： Revista Española de Cardiología, Revista bilingüe científica internacional, dedicada a las enfermedades cardiovasculares, es la publicación oficial de la Sociedad Española de Cardiología.